Henry Meds vs Mochi Health 2026: Compounded GLP-1 Programs Compared

BestMedsHub may receive compensation if you sign up via our links. This does not affect our editorial ratings.

The compounded GLP-1 telehealth market in 2026 is a smaller, more specialized space than the broad weight-loss platforms like Hims and Ro. Two of the most credible operators — Henry Meds and Mochi Health — built their reputations specifically around compounded semaglutide and tirzepatide before the FDA’s September 2025 compounding restrictions reshaped the entire category. How each company has adapted to the new rules tells you a lot about which one is the better fit for you in 2026.

This guide is the honest, side-by-side breakdown: real 2026 monthly costs, what compounded formulations each platform is offering now that semaglutide and tirzepatide are off the shortage list, how the clinical care actually feels, and which type of patient each one serves best. No influencer hype, no fabricated doctor quotes — just what we’d tell a friend who asked us to help choose.

At-a-Glance Comparison

Henry Meds: Deep Dive

Henry Meds built its reputation as one of the more transparent and patient-friendly compounded GLP-1 platforms during the 2023-2024 shortage era, and it’s carried that goodwill into 2026. The pitch has always been straightforward: a flat monthly price that bundles consultation, medication, shipping, and follow-up into a single line item, with no surprise fees and no aggressive upsells.

The intake process is structured and quick. You complete a health questionnaire covering BMI, comorbidities, medication history, and the standard GLP-1 contraindications (personal or family history of medullary thyroid carcinoma, MEN2 syndrome, pancreatitis, severe gastrointestinal disease, pregnancy). A licensed clinician reviews the file, and most patients hear back within 24-48 hours. If approved, the prescription goes to one of Henry’s partner compounding pharmacies, and medication typically ships within a few business days.

After September 2025, Henry pivoted its compounded offering to fit the FDA’s revised framework. Standard compounded semaglutide — the kind that was prevalent during the shortage — is no longer broadly available. What Henry now offers are personalized formulations: combinations with B-12, modified concentrations, or other patient-specific preparations that fall within the legal carve-out for compounding when a drug is not on the shortage list. This is the same legal framework every credible compounded GLP-1 operator is using in 2026, but Henry has been more transparent than most about how the formulations differ from what patients may remember.

What Henry does well: transparent pricing, fast clinical turnaround, consistent shipping, and a reputation for not aggressively pushing add-ons. The platform is well-suited for patients who know they want a compounded GLP-1, have done the homework, and want to start treatment without a heavy program structure.

Where Henry is weaker: behavioral and dietary support is light. There’s no included dietitian; the program is primarily medication delivery with clinician oversight. If you want a comprehensive obesity-medicine experience with nutrition coaching, Henry is not the right fit. State availability is also more limited than larger competitors — Henry operates in many but not all states, so verify availability during intake.

One practical strength: Henry’s clinicians are accessible by message for dose adjustments and side-effect concerns, and the platform has built a reasonable workflow for handling the GI side effects (nausea, constipation, early satiety) that drive most discontinuations in the first 8 weeks of GLP-1 therapy.

Mochi Health: Deep Dive

Mochi Health takes a different posture. Where Henry is essentially streamlined prescription fulfillment with clinical oversight, Mochi is built as a true obesity-medicine program. The $245/month program fee covers structured clinical care, registered dietitian access, behavior change support, and ongoing visits — the medication is billed separately, typically in the range that brings monthly totals to a similar ballpark as Henry's all-in pricing, depending on the dose and formulation.

The intake at Mochi is more involved. You'll complete a longer health and behavior questionnaire, may be asked to submit recent labs (or have them ordered through Mochi's lab network), and you're matched with both a clinician and a dietitian. Scheduled video visits are part of the standard cadence, not optional add-ons. The dietitian component is genuinely useful: nutrition-related side effects of GLP-1 medications — early satiety leading to inadequate protein intake, micronutrient gaps, constipation from low fiber — are real and underappreciated, and having a dietitian who actively addresses them is meaningfully better than figuring it out on your own.

Like Henry, Mochi has adapted its compounded offering for the post-September 2025 regulatory environment. The medication menu in 2026 includes personalized compounded semaglutide and tirzepatide formulations, with the specific formulation determined by clinical fit and the legal framework around personalized compounding. Mochi has been similarly transparent about the change.

What Mochi does well: clinical depth, dietitian access, structured program design, and a genuine focus on long-term outcomes rather than short-term medication delivery. The platform's framing — that GLP-1 medications work best alongside sustained behavior change — is consistent with how obesity medicine specialists practice in non-telehealth settings.

Where Mochi is weaker: the cost structure can feel heavier upfront because the program fee and medication are billed separately, and the more structured program isn't for everyone. Patients who just want a prescription filled may find Mochi's scaffolding excessive. The 12-month commitment framing is similar to Ro's — Mochi is built for patients who plan to stay on the program for at least a year.

How They're Priced in 2026

Pricing is where the structural differences between Henry and Mochi become concrete:

Henry Meds: Roughly $249-$349/month all-in. This bundles consultation, medication, shipping, and follow-up into a single monthly charge. The price varies by medication choice (semaglutide vs tirzepatide formulation) and dose. There are no separate consultation fees, no separate shipping fees, and no labs required for standard intake (though labs can be ordered if clinically indicated, at additional cost). The flat-fee model is one of Henry's strongest selling points — you know what you're paying.

Mochi Health: $245/month for the program, billed separately from medication. Medication costs vary by formulation and dose, generally pulling the all-in monthly cost into a similar range as Henry depending on the specifics. Mochi's pricing model is more transparent about what you're paying for the clinical program versus the medication itself, which some patients appreciate (especially if they want to use HSA/FSA funds against the program fee).

Hidden fees on both platforms are minimal but worth checking: lab work (if not included), supportive medications (anti-nausea adjuncts), and shipping for expedited orders. Neither platform charges cancellation fees, but neither refunds medication that has already shipped — a standard practice across compounded medication providers.

Manufacturer savings card eligibility is not really a factor here. NovoCare (Wegovy) and Zepbound's savings programs apply to brand-name medications dispensed through retail pharmacies — they don't apply to compounded formulations. Patients who have insurance that covers brand-name GLP-1s are usually better served by a platform like Ro that's set up to handle insurance and prior authorizations.

GLP-1 Medication Options and the FDA September 2025 Context

This is the most important section in this guide. The compounded GLP-1 landscape changed materially in September 2025, and any current decision needs to be made with the new framework in mind.

Here's what happened: In late 2024 and through 2025, the FDA formally determined that the shortages of semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) had resolved. Under federal law (specifically sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act), compounding pharmacies are not permitted to produce drugs that are essentially identical to FDA-approved medications when those medications are not on the shortage list. The shortage-era practice of widespread compounded semaglutide — where pharmacies were essentially producing copies of Ozempic for patients who couldn't access the brand — is no longer legal.

What's still legal: personalized compounded formulations. Compounding pharmacies can still produce formulations that are clinically different from the FDA-approved version: different doses, combinations with other active ingredients (B-12 is common, anti-nausea agents are sometimes included), or other patient-specific modifications based on a documented clinical rationale. This is the framework that Henry, Mochi, Hims, Ro, and essentially every credible operator has adopted.

What this means for you as a patient: the compounded medication you'll receive in 2026 is the same underlying drug class as what was prescribed in 2024, but the specific formulation has been adjusted to fit within the legal framework. The clinical effects — appetite reduction, slower gastric emptying, weight loss — are expected to be similar. Both Henry and Mochi have been transparent about this in their intake materials.

The alternative paths in 2026 are: (1) brand-name FDA-approved options (Wegovy, Zepbound) through insurance, which neither Henry nor Mochi specializes in, or (2) staying with compounded personalized formulations through platforms like these. Both are legitimate; the choice depends on insurance status and cost tolerance.

This is a complicated area of pharmaceutical law, and reasonable people disagree about the right policy. We're not offering legal advice here — we're describing what the FDA has stated and how the major telehealth platforms have responded.

Doctor and Ongoing Care Quality

Henry's care model is asynchronous-first with as-needed video. You message your care team for questions, dose adjustments, or side-effect concerns, and a clinician responds — sometimes the same one, sometimes a rotating team. Video visits are available when clinically indicated but aren't the default cadence. This works well for straightforward cases and patients who don't want scheduled visits eating their time. It works less well when you're early in titration, having significant side effects, or have a complicated medical history.

Mochi's care model is scheduled and structured. You have regular video visits with your clinician, plus dietitian sessions that address the nutritional implications of being on a GLP-1. The dietitian component is the biggest differentiator: meaningful weight-loss outcomes on GLP-1 medications depend on adequate protein intake, sustainable eating patterns, and the ability to navigate the side-effect arc without abandoning the medication. A dietitian who knows GLP-1-specific issues is worth real money.

Dose titration also differs. Henry tends to follow standardized titration schedules with adjustments when patients flag tolerance issues. Mochi is more individualized — holding patients at lower doses when side effects are significant or when weight loss is progressing well at the current dose. This is consistent with how obesity-medicine specialists generally practice in non-telehealth settings, and the evidence base supports it: aggressive titration when not needed adds side effects without proportionate benefit.

Side-effect support: both platforms have protocols for the standard issues (nausea, constipation, reflux, early satiety). Mochi's dietitian access makes the practical management noticeably easier; Henry's messaging-based support is adequate for most patients but less proactive.

Who Each Is Best For

Henry Meds is best for:

The informed self-starter. You've researched GLP-1s, you know you want compounded medication, and you want a straightforward path to a prescription with clinical oversight. You don't need a heavy program — you need transparent pricing, fast intake, and reliable shipping.

The cost-sensitive patient who values predictability. The all-in monthly price is a single line item with no surprises. You'd rather pay one bundled fee than worry about whether the program fee plus medication will end up exceeding your budget.

Mochi Health is best for:

The patient who wants a real program. You recognize that GLP-1s work best alongside sustained behavior change. You want a dietitian, scheduled clinician visits, and structured support. You're committed to a year-long program, not a three-month experiment.

The patient with nutritional complexity. You're concerned about protein intake, muscle preservation, or managing GI side effects. The dietitian access is genuinely valuable. You'd rather pay a bit more for the integrated care than try to figure out the nutrition piece on your own.

Real Customer Feedback Patterns

Patterns we see consistently across Reddit (r/Semaglutide, r/Mounjaro, r/loseit) and Trustpilot:

Henry Meds: Strong praise for transparent pricing, consistent shipping, and a no-pressure intake experience. Reviewers frequently mention that the all-in pricing model felt honest. Complaints cluster around two themes: (1) state availability limitations frustrate patients who discover Henry doesn't operate where they live, and (2) post-September 2025 confusion about the shift in compounded formulations — patients who understood the change going in were satisfied; those who didn't sometimes felt the formulation change was poorly communicated.

Mochi Health: Strong praise for clinical quality, dietitian access, and the obesity-medicine framing. Reviewers who engage with the full program tend to report durable behavior change alongside weight loss. Complaints cluster around cost (the program fee plus medication structure can feel front-loaded) and the structured-program intensity, which some patients find excessive when they just want a prescription. Cancellation friction is mentioned occasionally but doesn't appear to be a systemic issue.

Neither platform has the kind of patterned complaint structure that would raise safety concerns. Both are credible operators in a category that has plenty of less-credible competitors selling vague "GLP-1 access" without meaningful clinical oversight.

FAQ

Is compounded semaglutide still legal through Henry Meds or Mochi Health in 2026?

Only as personalized formulations, not as standard copies of Ozempic or Wegovy. Both platforms have adapted to the FDA's post-September 2025 framework, which permits compounded medications when they're clinically distinct from the FDA-approved version.

Which one is cheaper overall?

It's close. Henry's all-in pricing and Mochi's program-plus-medication structure generally land in a similar monthly range. Henry edges out on simplicity; Mochi includes more clinical services for the same approximate cost.

Can I use my HSA or FSA?

Generally yes for both, though the rules vary by plan. Mochi's program fee is more often reimbursable as a clinical service; medication costs are typically eligible on both platforms. Check with your benefits administrator.

What if I want brand-name Wegovy or Zepbound instead?

Neither Henry nor Mochi is the right platform for that. A platform like Ro that's set up for insurance navigation and manufacturer savings card stacking is a better fit.

How quickly should I expect to see results?

Clinical trials suggest meaningful weight loss begins in the first 4-8 weeks, with the largest losses occurring in the 6-12 month window. Real-world results vary based on adherence, dose, and behavior change. Mochi's dietitian support tends to improve long-term adherence.

What happens if I have severe side effects?

Both platforms have protocols for dose reduction or discontinuation. Severe symptoms — persistent vomiting, severe abdominal pain, signs of pancreatitis or gallbladder issues — warrant in-person care, not telehealth. Both platforms will direct you accordingly.

Does Medicaid cover anything through these platforms?

Generally no. Both Henry and Mochi are predominantly cash-pay. Most state Medicaid programs don't cover GLP-1s for obesity, with limited exceptions for type 2 diabetes coverage.

Can I switch between Henry and Mochi?

Yes. You'll restart intake on the new platform, and there may be a brief gap in medication. There's no medical reason you can't switch.

Final Verdict

Choose Henry Meds if: You want streamlined, transparent, cash-pay access to a compounded GLP-1 with reliable clinical oversight and predictable monthly pricing. You're a self-directed patient who doesn't need a heavy program structure.

Choose Mochi Health if: You want a true obesity-medicine program with dietitian access, structured clinical care, and behavior change support alongside the medication. You're committed to a year-long journey and want the strongest scaffolding for long-term outcomes.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 medications, including compounded formulations, carry serious risks and are not appropriate for everyone. Compounded medications are not FDA-approved and have different regulatory status than brand-name drugs; discuss the implications with a qualified healthcare provider before starting treatment. Affiliate disclosure: BestMedsHub maintains affiliate relationships with the providers reviewed in this article. If you sign up via our links, we may receive compensation. This does not affect our editorial ratings or content; pricing and program data is verified against publicly available information current to 2026.